A prospective case study found that applying GLP-1 receptor agonists (GLP-1 RAs) in T2DM patients with comorbid psoriasis reduced dermal γδ T cell numbers and IL-17 production, correlating with improved clinical severity of psoriasis (128). The gene discussed is IL17A; the disease is type 2 diabetes mellitus.